行情

GLMD

GLMD

Galmed制药
NASDAQ

实时行情|Nasdaq Last Sale

4.370
-0.070
-1.58%
盘后: 4.500 +0.13 +2.97% 16:06 11/15 EST
开盘
4.380
昨收
4.440
最高
4.510
最低
4.300
成交量
2.99万
成交额
--
52周最高
9.74
52周最低
3.418
市值
9,231.24万
市盈率(TTM)
-5.8050
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GLMD 新闻

  • Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/10 13:50
  • Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.11/09 03:57
  • The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings
  • Benzinga.11/06 13:21
  • Galmed Pharmaceuticals Q3 EPS $(0.21) Beats $(0.29) Estimate
  • Benzinga.11/06 12:18

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

GLMD 简况

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
展开

Webull提供Galmed Pharmaceuticals Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。